Tobacco Smoking, Genes &Nicotinic Receptors Habitual tobacco smoking is a complex trait with strong genetic influences. Genetic factors are estimated to account for 50-72% of the risk for developing nicotine dependence. The nicotinic acetylcholine receptor (nAChR) is the initial site of action of nicotine, the addictive chemical constituent of tobacco smoke and thus, is a primary candidate to carry genetic effects for tobacco smoking between generations. nAChR containing the 22-subunit (22-nAChR) in combination with 14 subunits are the most prevalent nAChR in brain, and are linked to the addictive properties of tobacco smoking. In our previous proposal, for aim 1, we demonstrated using [123I]5-IA 85380 SPECT imaging that these receptors are higher (26-36%) in the striatum, and throughout the cerebral cortex and cerebellum in tobacco smokers versus nonsmokers.
For aim 2 we evaluated the normalization of the receptor over the first month of abstinence, and in addition, evaluated in smokers that were able to abstain from smoking for longer periods of time up to 12 weeks of abstinence. The findings from this aim were very heterogenous, with some subjects showing decreases ranging from 4% to 43% in nAChR availability over the first month of abstinence and others showing no change. We have hypothesized that the variability in the regulatory effects of habitual tobacco smoking on nicotinic receptor availability is genetically determined. In the present proposal, we seek to validate this hypothesis through the following specific aims: 1) to determine if 22-nAChR availability is genetically determined in European-American never smokers. 2) to determine if the adaptive increase in 22-nAChR availability in European-American smokers is genetically determined and 3) to determine if the change in 22-nAChR availability over the first month of abstinence in smokers is genetically determined. The findings from these studies may provide definitive genetic and neurochemical phenotypic evidence that will allow in future studies for smokers to be stratified and tested for responses to various smoking cessation treatments.

Public Health Relevance

Smoking is the leading known cause of preventable death and disease. Despite the debilitating medical, economic and social costs of cigarette smoking, people continue to smoke. The persistence of this destructive behavior is a consequence of insufficient smoking cessation treatments to assist smokers in their efforts to quit smoking. The nicotinic acetylcholine receptor (nAChR) is a likely neurochemical substrate of the addiction to cigarette smoking. These studies will define the genes and brain chemicals that may help to design treatment studies that will ultimately help tailor smoking cessation treatments, they will decrease the incidence of smoking-related deaths and disease that plague the world today.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA015577-09
Application #
8447509
Study Section
Neural Basis of Psychopathology, Addictions and Sleep Disorders Study Section (NPAS)
Program Officer
Kautz, Mary A
Project Start
2002-07-01
Project End
2014-03-31
Budget Start
2013-04-01
Budget End
2014-03-31
Support Year
9
Fiscal Year
2013
Total Cost
$473,201
Indirect Cost
$107,623
Name
Yale University
Department
Psychiatry
Type
Schools of Medicine
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Moran-Santa Maria, Megan M; Vanderweyen, Davy C; Camp, Christopher C et al. (2018) Network Analysis of Intrinsic Functional Brain Connectivity in Male and Female Adult Smokers: A Preliminary Study. Nicotine Tob Res 20:810-818
Bhatt, Shivani; Hillmer, Ansel T; Nabulsi, Nabeel et al. (2018) Evaluation of (-)-[18 F]Flubatine-specific binding: Implications for reference region approaches. Synapse 72:
Hillmer, Ansel T; Li, Songye; Zheng, Ming-Qiang et al. (2017) PET imaging of ?7 nicotinic acetylcholine receptors: a comparative study of [18F]ASEM and [18F]DBT-10 in nonhuman primates, and further evaluation of [18F]ASEM in humans. Eur J Nucl Med Mol Imaging 44:1042-1050
Hillmer, A T; Esterlis, I; Gallezot, J D et al. (2016) Imaging of cerebral ?4?2* nicotinic acetylcholine receptors with (-)-[(18)F]Flubatine PET: Implementation of bolus plus constant infusion and sensitivity to acetylcholine in human brain. Neuroimage 141:71-80
Esterlis, Irina; Hillmer, Ansel T; Bois, Frederic et al. (2016) CHRNA4 and ANKK1 Polymorphisms Influence Smoking-Induced Nicotinic Acetylcholine Receptor Upregulation. Nicotine Tob Res 18:1845-52
Esterlis, Irina; Ranganathan, Mohini; Bois, Frederic et al. (2014) In vivo evidence for ?2 nicotinic acetylcholine receptor subunit upregulation in smokers as compared with nonsmokers with schizophrenia. Biol Psychiatry 76:495-502
Hannestad, Jonas O; Cosgrove, Kelly P; DellaGioia, Nicole F et al. (2013) Changes in the cholinergic system between bipolar depression and euthymia as measured with [123I]5IA single photon emission computed tomography. Biol Psychiatry 74:768-76
Cosgrove, Kelly P; Esterlis, Irina; McKee, Sherry A et al. (2012) Sex differences in availability of ?2*-nicotinic acetylcholine receptors in recently abstinent tobacco smokers. Arch Gen Psychiatry 69:418-27
Esterlis, Irina; Mitsis, Effie M; Batis, Jeffery C et al. (2011) Brain ?2*-nicotinic acetylcholine receptor occupancy after use of a nicotine inhaler. Int J Neuropsychopharmacol 14:389-98
Xie, Pingxing; Kranzler, Henry R; Krauthammer, Michael et al. (2011) Rare nonsynonymous variants in alpha-4 nicotinic acetylcholine receptor gene protect against nicotine dependence. Biol Psychiatry 70:528-36

Showing the most recent 10 out of 20 publications